All In Biotech

Drug Trial Radar · NCT07663032

A Study to Evaluate the Safety, Reactogenicity, and Immune Response of the GSK Vaccines Institute for Global Health (GVGH) Quadrivalent Pan-Salmonella Vaccine With and Without Alum in Healthy Young Adults

A Phase 1, Randomized, Controlled, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of the GVGH Quadrivalent Pan-Salmonella Vaccine With and Without Alum in Healthy Adults 18 to 45 Years of Age in Africa

Last checked: Nov 19, 2026Latest source record: Jul 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 196 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

196

Planned (sponsor's estimate)

Start

Jun 24, 2026

Primary completion

Nov 14, 2027

Study completion Nov 14, 2027

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Jun 23, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Triple (care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The current clinical study will evaluate the GVGH Quadrivalent Pan-Salmonella vaccine for the first time in healthy adults in Africa. The purpose of the current Phase 1 study is to evaluate the safety, reactogenicity, and the immune response induced by the Pan-Salmonella vaccine.

Conditions

  • Salmonella Infections

Interventions

  • Pan-Salmonella-with-Alum (Low dose) vaccineBiological

    Participants receive low dose of the Pan-Salmonella-with-Alum.

  • Pan-Salmonella-with-Alum (Full dose) vaccineBiological

    Participants receive full dose of the Pan-Salmonella-with-Alum.

  • Pan-Salmonella-without-Alum (Low dose) vaccineBiological

    Participants receive low dose of the Pan-Salmonella-without-Alum.

  • Pan-Salmonella-without-Alum (Full dose) vaccineBiological

    Participants receive full dose of the Pan-Salmonella-without-Alum.

  • Typhoid Vi conjugate vaccineBiological

    Participants receive Typhoid Vi conjugate vaccine as control

  • PlaceboOther

    Participants receive Placebo (saline solution) as control.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with solicited administration site eventsTime frame: From Day 1 to Day 7
  2. Number of participants with solicited administration site eventsTime frame: From Day 61 to Day 67
  3. Number of participants with solicited administration site eventsTime frame: From Day 181 to Day 187
  4. Number of participants with solicited systemic eventsTime frame: From Day 1 to Day 7
  5. Number of participants with solicited systemic eventsTime frame: From Day 61 to Day 67
  6. Number of participants with solicited systemic eventsTime frame: From Day 181 to Day 187
  7. Number of participants with unsolicited eventsTime frame: From Day 1 to Day 30
  8. Number of participants with unsolicited eventsTime frame: From Day 61 to Day 91
  9. Number of participants with unsolicited eventsTime frame: From Day 181 to Day 211
  10. Number of participants with serious adverse events (SAEs)Time frame: From Day 1 to Day 211
  11. Number of participants with adverse events (AEs) or SAEs leading to withdrawal from the study or discontinuation of study interventionTime frame: From Day 1 to Day 211
  12. Number of participants with changes from baseline or changes from normal values for hematological, renal, and hepatic panels test resultsTime frame: At Day 8
  13. Number of participants with changes from baseline or changes from normal values for hematological, renal, and hepatic panels test resultsTime frame: At Day 68
  14. Number of participants with changes from baseline or changes from normal values for hematological, renal, and hepatic panels test resultsTime frame: At Day 188

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Bloemfontein, South Africa · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.